Article Text

Download PDFPDF
Rofecoxib did not slow progression of dementia in patients with established Alzheimer’s disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with established Alzheimer’s disease (AD), does rofecoxib slow progression of dementia?

Clinical impact ratings Neurology ★★★★★☆☆ Geriatrics ★★★★★★★


Embedded ImageDesign:

randomised controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded {patients, clinicians, data collectors, outcome assessors, and data analysts}.*

Embedded ImageFollow up period:

12 months.

Embedded ImageSetting:

31 sites in the US.

Embedded ImagePatients:

692 patients who were ⩾50 years of age (mean age 76 y, 53% women), met standard research criteria for possible or probable AD, had mild or moderate dementia (Mini-Mental State Examination [MMSE] score 14–26 and a Clinical Dementia Rating [CDR] global score no worse than moderate dementia), and had a reliable informant or caregiver to accompany them to clinic visits and ensure that they …

View Full Text


  • * See glossary.

  • Information provided by author.

  • For correspondence: Dr C Lines, Merck Research Laboratories, Blue Bell, PA, USA.

  • Source of funding: Merck Research Laboratories.